**Somerset Indus Capital Partners Nears $275 Million Fund Closure**
Somerset Indus Capital Partners, a private equity firm specializing in healthcare, is on track to finalize its third fund at approximately $275 million by October. This comes with support from both existing and new limited partners, as confirmed by a senior executive. The firm has already met its initial target, securing commitments of $250 million, and anticipates a final close next month. Somerset plans to utilize a green-shoe option of up to 10%, backed by some of its previous fund’s limited partners.
The firm has seen a significant shift towards institutional capital, with Fund 2 comprising about 65% institutional investment, now rising to nearly 95%. This includes a diverse mix of development finance institutions (DFIs) from both India and abroad. The fund has attracted participation from a variety of sources, including European and American DFIs, a global investment company, prominent European institutions, one of India’s largest financial banks, insurance firms, family offices, and impact investors from Europe and Southeast Asia. The first close of the fund occurred in August 2024.
**Investment Focus and Strategy**
Somerset targets first-generation entrepreneurs, providing growth equity investments ranging from $15 million to $40 million in sectors such as healthcare delivery, pharmaceuticals, life sciences, medical devices, diagnostics, and related fields. The firm currently manages approximately $500 million in assets across three funds. Its portfolio features notable companies like Ujala Cygnus Hospitals, which enhances affordable healthcare in northern India, and Krsnaa Diagnostics, known for its cost-effective diagnostic services.
The firm’s successful track record with Fund 1, which yielded a 4.5x multiple on invested capital (MOIC) and a 4x distribution to paid-in capital (DPI) over a decade, has bolstered its fundraising efforts. Somerset has already begun deploying capital from its third fund, with investments in Cyrix Healthcare and Printmann Offset made in December 2024, and is currently assessing a third investment opportunity.
**Healthcare Sector Insights**
Sirdesai emphasized that healthcare has evolved from being merely recession-resistant to a sector characterized by consistent exits. He noted that many sector-agnostic funds now allocate about 20% of their portfolios to healthcare, with peers increasingly recognizing it as a distinct focus area. Within the healthcare landscape, Somerset is exploring new sub-segments, including advanced diagnostics such as cancer testing, point-of-care solutions, and specialty clinics, which Sirdesai described as “centers of excellence” that often yield higher profitability than traditional multi-specialty hospitals.
In conclusion, Somerset Indus Capital Partners is poised for a successful close of its third fund, reflecting a growing confidence in the healthcare sector and a strategic focus on innovative investment opportunities.
**FAQ**
**What is Somerset Indus Capital Partners’ investment strategy?**
Somerset Indus Capital Partners focuses on investing in first-generation entrepreneurs within the healthcare sector, providing growth equity investments typically ranging from $15 million to $40 million.
